Adicet Bio, Inc.
Adicet Bio, Inc. (ACET) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
acet · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Adicet Bio, Inc. (ACET) measures how much investors pay for each dollar of the company's trailing earnings. ACET's current PE ratio of N/A is calculated by dividing its stock price of $7.22 by its TTM earnings per share of -$10.13.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2008 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 8 fiscal years · Front-end computedMinQ1 · 25%174.4x
MedianQ3 · 75%392.4x
Max
At N/A, ACET's current P/E is lower than in 0% of its annual fiscal year readings over the past 8 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Adicet Bio, Inc.You ACET | $67M | N/A | — | -$10.13 |
 Acrivon Therapeutics, Inc. Common Stock ACRV | $44M | N/A | — | -$2.02 |
 Adagene Inc. ADAG | $123M | N/A | — | -$0.47 |
 CervoMed Inc. CRVO | $27M | N/A | — | -$2.98 |
 Gain Therapeutics, Inc. GANX | $72M | N/A | — | -$0.61 |
 Werewolf Therapeutics, Inc. HOWL | $19M | N/A | — | -$1.32 |
 Immunic, Inc. IMUX | $119M | N/A | — | -$6.24 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-16.95 | — | |
2024-12-31 FY2024 | — | $-21.33 | — | |
2023-12-31 FY2023 | — | $-53.03 | — | |
2022-12-31 FY2022 | — | $-27.18 | — | |
2021-12-31 FY2021 | — | $-32.05 | — | |
2020-12-31 FY2020 | — | $-80.17 | — | |
2019-12-31 FY2019 | — | $-24.26 | — | |
2018-12-31 FY2018 | — | $-4.99 | — | |
2017-06-30 FY2017 | — | $-20.19 | — | |
2016-06-30 FY2016 | — | $-0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Adicet Bio, Inc. (ACET) measures how much investors pay for each dollar of the company's trailing earnings. ACET's current PE ratio of N/A is calculated by dividing its stock price of $7.22 by its TTM earnings per share of -$10.13.
Frequently asked questions
ACET pe ratio · 6 questionsACET's current PE ratio is N/A as of 2026-06-09, based on a stock price of $7.22 and TTM EPS of -$10.13. Data sourced from Financial Modeling Prep via ACET's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Adicet Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09